Authors: Pressel, SL Davis, BR Wright, JT Geraci, TS Kingry, C Ford, CE Piller, LB Bettencourt, J Kimmel, B Lusk, C Parks, H Simpson, LM Nwachuku, C Furberg, CD

Citation: Sl. Pressel et al., Operational aspects of terminating the doxazosin arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), CONTR CL TR, 22(1), 2001, pp. 29-41

Authors: Grimm, RH Margolis, KL Papademetriou, V Cushman, WC Ford, CE Bettencourt, J Alderman, MH Basile, JN Black, HR DeQuattro, V Eckfeldt, J Hawkins, CM Perry, HM Proschan, M

Citation: Rh. Grimm et al., Baseline characteristics of participants in the Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial (ALLHAT), HYPERTENSIO, 37(1), 2001, pp. 19-27

Authors: Furberg, CD Wright, JT Davis, BR Cutler, JA Alderman, M Black, H Cushman, W Grimm, R Haywood, LJ Leenen, F Oparil, S Perry, HM Probstfield, J Whelton, P Payne, G Nwachuku, C Gordon, D Proschan, M Frommer, P Einhorn, P Hawkins, M Ford, C Pressel, S Piller, L Lusk, C Bettencourt, J Kimmel, B Geraci, T Walsh, S Rahman, M Juratovac, A Pospisil, R Brennan, K Carroll, L Sullivan, S Barone, G Christian, R Feldman, S Lucente, T Lewis, CE Jenkins, K McDowell, P Johnson, J Kingry, C Letterer, R Margolis, K Holland, L Jaeger-Fox, B Williamson, J Louis, G Ragusa, P Williard, A Ferguson, RS Tanner, J Eckfeldt, J Crow, R Pelosi, J

Citation: Cd. Furberg et al., Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone - The Antihypertensive and Lipid-Lowering Treatment toPrevent Heart Attack Trial (ALLHAT), J AM MED A, 283(15), 2000, pp. 1967-1975

Authors: Hanley, K Komuves, LG Bass, NM He, SS Jiang, Y Crumrine, D Appel, R Friedman, M Bettencourt, J Min, K Elias, PM Williams, ML Feingold, KR

Citation: K. Hanley et al., Fetal epidermal differentiation and barrier development in vivo is accelerated by nuclear hormone receptor activators, J INVES DER, 113(5), 1999, pp. 788-795